← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #143 OF 1,000 MOST-CITED

Following/documenting laboratory controls

FDA cited this observation 163 times across 155 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs163
BY FISCAL YEAR
FY202611
FY202513
FY202418
FY202321
FY202214
FY20215
FY202021
FY201925
FY201823
FY201712

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.9× the rate of the average FDA-cited firm (32.3% vs 8.3%), across 155 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Established laboratory control mechanisms are not followed.

Canyon Rush, LLC · Rush, New York · Drugs · 2026-05-15

Established test procedures are not documented at the time of performance.

Hanlim Pharm Co. Ltd. · Yongin · Drugs · 2026-04-24

Established specifications, standards, sampling plans, test procedures and laboratory control mechanisms are not followed and documented at the time of performance.

Baxter Healthcare Corporation · Round Lake, Illinois · Drugs · 2026-04-02

Established sampling plans are not followed.

Gilead Sciences, Inc. · La Verne, California · Drugs · 2026-02-18

Established laboratory control mechanisms are not followed.

Eugia Pharma Specialities Limited · Sangareddy · Drugs · 2026-02-06

Established test procedures and laboratory control mechanisms are not followed.

Fenwal International, Inc. · Maricao, Puerto Rico · Drugs · 2026-02-05

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →